- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05026424
Glycemic Response in Adults With Diabetes
October 20, 2021 updated by: Société des Produits Nestlé (SPN)
Glucose and Insulin Response in Adults With Type 2 Diabetes
This will be a randomized crossover design with oral nutrition supplement interventions.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This will be a randomized crossover design with two oral nutrition supplement interventions.
The subjects will be randomized to one of two interventions on two separate study days, one week apart.
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Tustin, California, United States, 92780
- Orange County Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 20-75 years
- Type 2 diabetes controlled with diet or diet and metformin (Glucophage)
- Hemoglobin A1C less than 9.0%
- Fasting blood glucose less than 180 mg/dl
- Hematocrit levels within normal limits
- Having obtained his/her informed consent
Exclusion Criteria:
- Abnormal thyroid function
- Creatinine >2.0 mg/dl
- Potassium <3.5 mEq/l
- Gastrointestinal disease: ulcer, gastritis, diarrhea, gastroparesis, vomiting
- Currently unstable diabetes or under treatment for cancer, heart disease, renal disease
- Patients with anemia
- Current insulin therapy or insulin therapy within the past month
- Patient who are pregnant
- Allergies to milk, soy or any component of the test product
- Patient who in the investigators assessment cannot be expected to comply with treatment
- Patients with anemia
- Currently participating in another clinical trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Active Comparator: Oral Nutrition Supplement Control
The control study intervention is an oral drink that contain protein, carbohydrate and fat and are intended for use as supplemental nutrition.
|
Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as supplemental nutrition.
|
Active Comparator: Active Comparator: Oral Nutrition Supplement Test
The test study intervention is an oral drink that contain protein, carbohydrate and fat and are intended for use as supplemental nutrition for people living with diabetes.
|
Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat designed for people living with diabetes and intended for use as supplemental nutrition.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post-prandial glycemic markers
Time Frame: [Time Frame: Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes]
|
Area under the blood glucose curve (AUC 0-240 minutes)
|
[Time Frame: Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes]
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post-prandial insulin markers
Time Frame: [Time Frame: Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes]
|
Area under the insulin curve (AUC 0-240 minutes)
|
[Time Frame: Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes]
|
Insulinogenic index
Time Frame: [Time Frame: Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes]
|
Insulinogenic index (change in Ins30/change in Glu30)
|
[Time Frame: Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes]
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 2, 2021
Primary Completion (Actual)
September 30, 2021
Study Completion (Actual)
October 5, 2021
Study Registration Dates
First Submitted
August 24, 2021
First Submitted That Met QC Criteria
August 24, 2021
First Posted (Actual)
August 30, 2021
Study Record Updates
Last Update Posted (Actual)
October 27, 2021
Last Update Submitted That Met QC Criteria
October 20, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21.04.US.HCN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Balance oral nutritional drink - control
-
University of NottinghamRecruiting
-
Fresenius KabiCompleted
-
University of SouthamptonNational University Hospital, Singapore; Singapore Institute for Clinical Sciences and other collaboratorsEnrolling by invitationNeurobehavioral Manifestations | Allergy | Microbial Colonization | Growth Disorders | Atopic Dermatitis | Obesity, Childhood | Metabolic Disturbance | Cognition | Lifestyle | Breastfeeding | Nutrition, Healthy | AtopySingapore, United Kingdom, New Zealand
-
Taipei Medical UniversityMeiji Co., Ltd.CompletedMalnutrition ElderlyTaiwan
-
NestléCompleted
-
Nutricia UK LtdSuspended
-
Fondazione IRCCS Policlinico San Matteo di PaviaIRCCS Ospedale San RaffaeleNot yet recruiting
-
University of SouthamptonNational University Hospital, Singapore; Singapore Institute for Clinical Sciences and other collaboratorsCompletedHyperglycemiaSingapore, United Kingdom, New Zealand
-
Maastricht University Medical CenterTop Institute Food and NutritionCompleted